FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090959990> ?p ?o ?g. }

• W3090959990 endingPage "2611" @default.
• W3090959990 startingPage "2598" @default.
• W3090959990 abstract "Abstract S100A4 oncoprotein plays a critical role during prostate cancer progression and induces immunosuppression in host tissues. We hypothesized that S100A4-regulated oncogenic activity in immunosuppressed prostate tumors promotes growth of neoplastic cells, which are likely to become aggressive. In the current study, we investigated whether biopsy-S100A4 gene alteration independently predicts the outcome of disease in patients and circulatory-S100A4 is druggable target for treating immunosuppressive prostate cancer. Aided by DECIPHER-genomic test, we show biopsy-S100A4 overexpression as predictive of (i) poor ADT response and (ii) high risk of mortality in 228 radical prostatectomy-treated patients. Furthermore, analysis of tumor genome data of more than 1,000 patients with prostate cancer (PRAD/SU2C/FHCRC studies) validated the association of S100A4-alteration to poor survival and metastasis. We show that increased serum-S100A4 levels are associated to the prostate cancer progression in patients. The prerequisite for metastasis is the escape of tumor cells via vascular system. We show that extracellular-S100A4 protein as a growth factor induces vascular transmigration of prostate cancer cells and bone demineralization thus forms an ideal target for therapies for treating prostate cancer. By employing surface plasmon resonance and isothermal titration calorimetry, we show that mab6B12 antibody interacts with and neutralizes S100A4 protein. When tested for therapeutic efficacy, the mab6B12 therapy reduced the (i) osteoblastic demineralization of bone-derived MSCs, (ii) S100A4-target (NFκB/MMP9/VEGF) levels in prostate cancer cells, and (iii) tumor growth in a TRAMPC2 syngeneic mouse model. The immuno-profile analysis showed that mAb6B12-therapy (i) shifted Th1/Th2 balance (increased Stat4+/T-bet+ and decreased GATA2+/CD68+/CD45+/CD206+ cells); (ii) modulated cytokine levels in CD4+ T cells; and (iii) decreased levels of IL5/6/12/13, sTNFR1, and serum-RANTES. We suggest that S100A4-antibody therapy has clinical applicability in treating immunosuppressive prostate cancer in patients." @default.
• W3090959990 created "2020-10-08" @default.
• W3090959990 creator A5003023498 @default.
• W3090959990 creator A5004689576 @default.
• W3090959990 creator A5012516349 @default.
• W3090959990 creator A5014353611 @default.
• W3090959990 creator A5020745161 @default.
• W3090959990 creator A5025580110 @default.
• W3090959990 creator A5034204748 @default.
• W3090959990 creator A5039738587 @default.
• W3090959990 creator A5050104830 @default.
• W3090959990 creator A5050241036 @default.
• W3090959990 creator A5064387672 @default.
• W3090959990 creator A5069041955 @default.
• W3090959990 creator A5069933385 @default.
• W3090959990 creator A5090940356 @default.
• W3090959990 date "2020-12-01" @default.
• W3090959990 modified "2023-10-18" @default.
• W3090959990 title "Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy<i>S100A4</i>as a Clinical Predictor" @default.
• W3090959990 cites W1532176619 @default.
• W3090959990 cites W1534923950 @default.
• W3090959990 cites W1581834767 @default.
• W3090959990 cites W1915253743 @default.
• W3090959990 cites W1946855779 @default.
• W3090959990 cites W1963256408 @default.
• W3090959990 cites W1977918192 @default.
• W3090959990 cites W1998343146 @default.
• W3090959990 cites W2017241547 @default.
• W3090959990 cites W2018760769 @default.
• W3090959990 cites W2021653386 @default.
• W3090959990 cites W2037614261 @default.
• W3090959990 cites W2040016252 @default.
• W3090959990 cites W2040773852 @default.
• W3090959990 cites W2042898512 @default.
• W3090959990 cites W2049920293 @default.
• W3090959990 cites W2059085904 @default.
• W3090959990 cites W2069380387 @default.
• W3090959990 cites W2075873658 @default.
• W3090959990 cites W2079101269 @default.
• W3090959990 cites W2081630195 @default.
• W3090959990 cites W2088592436 @default.
• W3090959990 cites W2093731683 @default.
• W3090959990 cites W2109301975 @default.
• W3090959990 cites W2113446988 @default.
• W3090959990 cites W2122861585 @default.
• W3090959990 cites W2123612933 @default.
• W3090959990 cites W2127063361 @default.
• W3090959990 cites W2147820545 @default.
• W3090959990 cites W2149441684 @default.
• W3090959990 cites W2165703404 @default.
• W3090959990 cites W2167717666 @default.
• W3090959990 cites W2169772835 @default.
• W3090959990 cites W2397859367 @default.
• W3090959990 cites W2507471150 @default.
• W3090959990 cites W2592401125 @default.
• W3090959990 cites W2615491662 @default.
• W3090959990 cites W2616193394 @default.
• W3090959990 cites W2726409463 @default.
• W3090959990 cites W2727705472 @default.
• W3090959990 cites W2736730167 @default.
• W3090959990 cites W2766205090 @default.
• W3090959990 cites W2781615683 @default.
• W3090959990 cites W2792766323 @default.
• W3090959990 cites W2801493685 @default.
• W3090959990 cites W2890561948 @default.
• W3090959990 cites W2975372829 @default.
• W3090959990 cites W2988688765 @default.
• W3090959990 cites W4246016891 @default.
• W3090959990 cites W4376999540 @default.
• W3090959990 doi "https://doi.org/10.1158/1535-7163.mct-20-0410" @default.
• W3090959990 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32999046" @default.
• W3090959990 hasPublicationYear "2020" @default.
• W3090959990 type Work @default.
• W3090959990 sameAs 3090959990 @default.
• W3090959990 citedByCount "6" @default.
• W3090959990 countsByYear W30909599902021 @default.
• W3090959990 countsByYear W30909599902022 @default.
• W3090959990 countsByYear W30909599902023 @default.
• W3090959990 crossrefType "journal-article" @default.
• W3090959990 hasAuthorship W3090959990A5003023498 @default.
• W3090959990 hasAuthorship W3090959990A5004689576 @default.
• W3090959990 hasAuthorship W3090959990A5012516349 @default.
• W3090959990 hasAuthorship W3090959990A5014353611 @default.
• W3090959990 hasAuthorship W3090959990A5020745161 @default.
• W3090959990 hasAuthorship W3090959990A5025580110 @default.
• W3090959990 hasAuthorship W3090959990A5034204748 @default.
• W3090959990 hasAuthorship W3090959990A5039738587 @default.
• W3090959990 hasAuthorship W3090959990A5050104830 @default.
• W3090959990 hasAuthorship W3090959990A5050241036 @default.
• W3090959990 hasAuthorship W3090959990A5064387672 @default.
• W3090959990 hasAuthorship W3090959990A5069041955 @default.
• W3090959990 hasAuthorship W3090959990A5069933385 @default.
• W3090959990 hasAuthorship W3090959990A5090940356 @default.
• W3090959990 hasBestOaLocation W30909599901 @default.
• W3090959990 hasConcept C121608353 @default.
• W3090959990 hasConcept C126322002 @default.
• W3090959990 hasConcept C142724271 @default.
• W3090959990 hasConcept C2776235491 @default.

• next